文献速递颈动脉与弓上血管

颈动脉近闭塞的系统综述与更新荟萃分析

A Systematic Review and Updated Metaanalysis for Carotid Near-Occlusion.
PubMed 文献 · Ann Vasc Surg · 2019-11-07

结果显示介入组长期次要结局发生率为4.26/100人年,单纯最佳药物治疗(BMT)组为13.3/100人年;颈动脉内膜剥脱术(CEA)与颈动脉支架置入术(CAS)在围手术期风险和长期风险上无显著差异。

要点

  • CNO占症状性颈动脉狭窄的3%,占严重(≥70%)症状性狭窄的约20%。
  • BMT组长期次要结局发生率13.3/100人年,高于介入组4.26/100人年。
  • CEA与CAS的围手术期风险及长期风险无显著差异。

核心结论

  • 单纯最佳药物治疗(BMT)可能不足以支持CNO患者获得优于CEA或CAS的预后。
  • 接受CAS与CEA的CNO患者在围手术期和长期随访中均未发现显著差异。

研究设计与样本

  • 主要结局为干预后30天内的任何卒中、死亡和心肌梗死(MI),以发生率(IR)评估CEA和CAS的手术风险。
  • 次要结局为随访期间的同侧卒中、神经源性或心源性死亡和MI,以IR评估长期风险。
  • 以每人年(p-y)的次要结局IR和再狭窄率评估长期风险与再狭窄。

主要发现

  • 介入组次要结局汇总IR为4.26/100人年(95%CI 2.92-6.20/100人年;异质性I2=56.1%,P<0.01;Egger检验P=0.73)。
  • BMT组次要结局汇总IR为13.3/100人年(95%CI 5.54-31.95/100人年;异质性I2=88.3%,P<0.01;Egger检验P=0.76)。
  • CEA手术风险为4.82%(95%CI 3.07-7.55%),CAS手术风险为5.39%(95%CI 3.69-7.88%),两者无显著差异。
  • CEA长期风险为4.47/100人年(95%CI 3.35-5.97/100人年),CAS长期风险为4.71/100人年(95%CI 2.37-9.37/100人年),两者无显著差异。

临床怎么用

  • 对于CNO患者,不应仅依赖最佳药物治疗,应考虑CEA或CAS等介入治疗以改善预后。
  • CEA与CAS在围手术期风险和长期风险上无显著差异,治疗方式选择可个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carotid near-occlusion (CNO) is distal luminal collapse of the internal carotid artery beyond a tight stenosis. CNO is a relatively rare condition accounting for 3% in symptomatic carotid stenosis and about 20% in severe (≥70%) symptomatic stenosis. The optimal treatment for CNO remains controversial. METHODS: This systematic review and metaanalysis were performed in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines (MOOSE). We searched MEDLINE, the Cochrane Library, and EMBASE for articles published from inception date to November 2018. Methodological Index for Non-randomized Studies (MINORS) was used to evaluate the methodological quality of studies. We defined primary outcome as any stroke, death and myocardial infarction (MI) within 30 days after intervention and the operative risks of carotid endarterectomy (CEA) and carotid artery stenting (CAS) were evaluated by the incidence rate (IR) of the primary outcome. Secondary outcome was defined as ipsilateral stroke, neurogenic or cardiac death and MI during the follow-up. Long-term risk was evaluated by the IR of secondary outcome. The analyses used the IRs of secondary outcome and restenosis per person-year (p-y) were performed to evaluate long-term risk and restenosis. Pooled analyses of different therapy groups were calculated. RESULTS: Twenty-eight articles of 26 studies met the inclusion criteria and were eligible for pooled analysis. Pooled IR of secondary outcome was 4.26 per 100 p-ys (95% CI, 2.92-6.20 per 100 p-ys) in intervention group (heterogeneity, I2 = 56.1%, P < 0.01; Egger test, P = 0.73) and 13.3 per 100 p-ys (95% CI, 5.54-31.95 per 100 p-ys) in best medical treatment (BMT) group (heterogeneity, I2 = 88.3%, P < 0.01; Egger test, P = 0.76). No significant difference was demonstrated in operative risk (CEA: 4.82%, 95% confidence interval [CI]: 3.07-7.55%; CAS: 5.39%, 95% CI: 3.69-7.88%) and long-term risk (CEA: 4.47 per 100 p-ys, 95% CI: 3.35-5.97 per 100 p-ys; CAS: 4.71 per 100 p-ys, 95% CI: 2.37-9.37 per 100 p-ys) between CEA and CAS group. CONCLUSIONS: BMT alone may be not enough to support a better prognosis than CEA or CAS for patients with CNO. No significant difference was found between patients with CNO who underwent CAS and CEA in both perioperative period and long-term follow-up.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Xue S, Tang X, Zhao G, et al. A Systematic Review and Updated Metaanalysis for Carotid Near-Occlusion. Ann Vasc Surg. 2019. PMID: 31706996. doi:10.1016/j.avsg.2019.10.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。